Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.C. Moellering, G.M. Eliopoulos, D.E. Sentochnik.
The carbapenems: New broad spectrum beta-lactam antibiotics.
J Antimicrob Chemother, SA (1989), pp. 1-7
[2.]
J. Martínez Lacasa, J. Garau.
Papel de los carbapenémicos en el tratamiento de la infección nosocomial.
Enferm Infecc Microbiol Clin, S1 (1997), pp. 78-85
[3.]
D.M. Livermore, N. Woodford.
Carbapenemases: A problem in waiting?.
Curr Opin Microbiol, 3 (2000), pp. 489-495
[4.]
F. Fernández-Cuenca, A. Pascual, A. Ribera, J. Vila, G. Bou, J.M. Cisneros, et al.
Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 267-271
[5.]
L. Gallego, M.J. Canduela, E. Sevillano, I. Pujana, F. Calvo, A. Umaran, et al.
Detección de carbapenemasas en clones de Acinetobacter baumannii resistentes a imipenem.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 262-266
[6.]
E. Bergogne-Berezin.
The increasing role of Acinetobacter species as nosocomial pathogens.
Curr Infect Dis Rep, 3 (2001), pp. 440-444
[7.]
E. Bergogne-Berezin, K.J. Towner.
Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features.
Clin Microbiol Rev, 9 (1996), pp. 148-165
[8.]
J. Vila, J. Ruiz, M. Navia, B. Becerril, I. García, S. Perea, et al.
Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain.
J Clin Microbiol, 37 (1999), pp. 758-761
[9.]
D. Landman, J.M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravishankar, et al.
Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.
Arch Intern Med, 162 (2002), pp. 1515-1520
[10.]
G. Bou, G. Cervero, M.A. Domínguez, C. Quereda, J. Martínez-Beltrán.
Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases.
J Clin Microbiol, 38 (2000), pp. 3299-3305
[11.]
X. Corbella, A. Montero, M. Pujol, M.A. Domínguez, J. Ayats, M.J. Argerich, et al.
Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.
J Clin Microbiol, 38 (2000), pp. 4086-4095
[12.]
A.C. Gales, R.N. Jones, K.R. Forward, J. Liñares, H.S. Sader, J. Verhoel.
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999.
Clin Infect Dis, 32 (2001), pp. 104-113
[13.]
J.A. Karlowski, D.C. Draghi, M.E. Jones, C. Thornsberry, I.R. Friedland, D.F. Sahm.
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.
J Clin Microbiol, 47 (2003), pp. 1681-1688
[14.]
P.J. Turner, J.M. Greenhalgh.
MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospital, 1997-2000.
Clin Microbiol Infect, 9 (2003), pp. 563-567
[15.]
T. Kohler, M. Michea-Hamzehpour, S.F. Epp, J.C. Pechere.
Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems.
Antimicrob Agents Chemother, (1999), pp. 424-427
[16.]
F. Fernández-Cuenca, L. Martínez-Martínez, M.C. Conejo, J.A. Ayala, E.J. Perea, A. Pascual.
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii.
J Antimicrob Chemother, 51 (2003), pp. 565-574
[17.]
D.M. Livermore.
β-lactamases in laboratory and clinical resistance.
Clin Microbiol Rev, 8 (1997), pp. 557-584
[18.]
P. Nordmann, L. Poirel.
Emerging carbapenemases in Gram-negative aerobes.
Clin Microbiol Infect, 8 (2002), pp. 321-331
[19.]
R. Paton, R.S. Miles, J. Hood, S.G.B. Amyes.
ARI-1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii.
Int J Antimicrob Agents, 2 (1993), pp. 81-88
[20.]
F. López-Otsoa, L. Gallego, K.J. Towner, L. Tysall, N. Woodford, D.M. Livermore.
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.
J Clin Microbiol, 40 (2002), pp. 4741-4743
[21.]
X. Corbella, J. Ariza, C. Ardanuy, M. Vuelta, F. Tubau, M. Sora, et al.
Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.
J Antimicrob Chemother, 42 (1998), pp. 793-802
[22.]
A.S. Levin, A.A. Barone, J. Penco, M.V. Santos, I.S. Marinho, E.A. Arruda, et al.
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Clin Infect Dis, 28 (1999), pp. 1008-1011
[23.]
C. Tascini, F. Menichetti, S. Bozza, A. Del Favero, F. Bistoni.
Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii.
J Antimicrob Chemother, 42 (1998), pp. 270-271
[24.]
M.D. Appleman, H. Belzberg, D.M. Citron, P.N. Heseltine, A.E. Yellin, J. Murray, et al.
In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.
Antimicrob Agents Chemother, 44 (2000), pp. 1035-1040
[25.]
M.J. Rodríguez-Hernández, J. Pachón, C. Pichardo, L. Cuberos, J. Ibáñez-Martínez, A. García-Curiel, et al.
Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.
J Antimicrob Chemother, 45 (2000), pp. 493-501
[26.]
F. Fernández-Cuenca, L. Martínez-Martínez, A. Pascual, E.J. Perea.
In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinetobacter baumannii.
Chemotherapy, 49 (2003), pp. 24-26
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
